VCs: Venture funding grows, with more money for startups

John Carroll That IPO boom was just what the VC doctor ordered. Between high-priced buyout deals and new offerings, the venture funds got the exits they needed to look good to investors ...

Impax cuts nearly 50 employees to save money

Eric Palmer Impax Laboratories, which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D ...

Celebrity pitch-folks may not be worth the money, study finds

Tracy Staton Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods? FiercePharma ...

How to save money via adherence? Let us count the (possible) ways

Carly Helfand Patients, pharmacy benefits managers and drugmakers alike are trying to figure out how to save money through further generics use and better prescription adherence. FiercePharma ...

Regeneron execs score $140M payday as Eylea mints money

Tracy Staton How much is a wildly successful drug worth? For Regeneron’s top executives, the answer is $ 140 million. With its vision-loss drug beating all sales expectations ...

U.S. adults still skipping pills to save money, CDC study finds

Tracy Staton Medicare Part D keeps patients on their meds. That's the upside of a new study that shows U.S. adults are still skipping doses to save money. And patients who don't ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS